---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-24-000050"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:41:06.523388+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q2 net sales down 6.3% YoY; Life Science weak, Diagnostics up 2.1%; board adds $500M buyback

## Summary
- Q2 net sales $638.5M, -6.3% YoY; Life Science $250.5M (-16.5%), Diagnostics $387.9M (+2.1%).
- Gross margin improved to 55.6% from 53.2%; operating income $101.5M vs $89.6M YoY.
- Net loss $2,165.5M ($76.26 diluted EPS) mainly due to non-cash fair value adjustment of Sartorius investment.
- CEO expects more modest pace of market recovery than originally anticipated.
- Board authorized additional $500M share repurchase; total available ~$578M as of July 31, 2024.

## SEC filing metadata
- accession: 0000012208-24-000050
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220824000050/0000012208-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220824000050/bio-20240729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-24-000050
- JSON: https://secwatch.observer/filing/0000012208-24-000050.json
- Plain text: https://secwatch.observer/filing/0000012208-24-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.